Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Endocrine Therapy in HR+/HER2- SNF3-subtype Early Breast Cancer
NCT05891093Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluzoparib in breast cancer, sponsored by Fudan University. Started Jun 2023; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05891093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891093.